HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25

Benzinga Newsdesk www.benzinga.com Positive 66.1%

Neg 0% Neu 0% Pos 66.1%

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $19 to $25.